Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease
Table 1
Demographic baseline characteristics of the 246 randomized and treated subjects who had ophthalmologic data.
Randomized and treated set
Pramipexole
Ropinirole
Age in years, mean ± SD
57.5 ± 9.3
59.1 ± 8.7
Range
35–80
35–78
36–80
Age group, n (%)
<50
40 (16.3)
23 (19.0)
17 (13.6)
50 to <65
145 (58.9)
71 (58.7)
74 (59.2)
65 to <75
51 (20.7)
21 (17.4)
30 (24.0)
≥75
10 (4.1)
6 (5.0)
4 (3.2)
Men, n (%)
157 (63.8)
79 (65.3)
78 (62.4)
Women, n (%)
89 (36.2)
42 (34.7)
47 (37.6)
Race, n (%)
Asian
2 (0.8)
1 (0.8)
1 (0.8)
African American
10 (4.1)
7 (5.8)
3 (2.4)
Caucasian
234 (95.1)
113 (93.4)
121 (96.8)
Time in years since PD diagnosis, mean ± SD
1.13 ± 1.46
0.97 ± 1.15
1.29 ± 1.70
Median
0.51
0.46
0.58
Range
0.0–9.4
0.0–5.2
0.0–9.4
Hoehn–Yahr stage, n (%)
0
0
0
0
1
51 (20.7)
28 (23.1)
23 (18.4)
1.5
30 (12.2)
11 (9.1)
19 (15.2)
2
142 (57.7)
71 (58.7)
71 (56.8)
2.5
13 (5.3)
8 (6.6)
5 (4.0)
3
10 (4.1)
3 (2.5)
7 (5.6)
4
0
0
0
5
0
0
0
Sum of the UPDRS part II and part III total scores, mean ± SD
30.4 ± 12.7
28.8 ± 11.6
31.9 ± 13.4
Alcohol history, n (%)
Does not drink
95 (38.6)
46 (38.0)
49 (39.2)
Number of patients with average consumption (not regarded as problematic by investigators)
